Physician profile
Alysha Cunningham
NPI 1649008707
$2,593.46
in general payments reported to CMS, 2019-2025
18 companies · $1,475 in 2025
The $1,475 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,119 · 2025: $1,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $99.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.96 |
| Education | $99.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $488.08 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $393.11 | 2024-2025 | Caplyta |
| Axsome Therapeutics, INC. | $294.90 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $240.36 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $190.82 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $182.93 | 2025 | Austedo Xr |
| Abbvie INC. | $179.53 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.91 | 2024-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $95.25 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $91.48 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $56.95 | 2024-2025 | Ingrezza |
| Neos Therapeutics, LP | $53.63 | 2024-2025 | Adzenys Xr-Odt |
| Indivior INC. | $52.26 | 2025 | Sublocade |
| Lundbeck LLC | $50.88 | 2025 | Rexulti |
| Corium, LLC | $27.30 | 2024 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.44 | 2025 | Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $18.54 | 2024 | Quviviq |
| Almatica Pharma LLC | $17.09 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysha Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.